Dynavax’s SD-101 and 4SC’s Domatinostat Demonstrate Synergy and Induce a Systemic Anti-tumor Response in Preclinical Models
April 01, 2019 13:00 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif. and PLANEGG-MARTINSRIED, Germany, April 01, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) and 4SC AG (FSE Prime Standard: VSC) today announced the...
Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults
March 28, 2019 16:05 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines...
Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019
March 20, 2019 16:20 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel...
Dynavax Exercises Option for $75 Million in Non-Dilutive Debt
March 18, 2019 16:05 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has exercised its option to draw down $75 million of non-dilutive capital...
Dynavax to Present at 39th Annual Cowen Healthcare Conference
March 06, 2019 16:05 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel...
Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 16:05 ET
|
Dynavax Technologies Corporation
Fourth quarter 2018 HEPLISAV-B® net product revenue of $3.9 millionPhase Ib/2 safety data for inhaled DV281 will be presented at the AACR Annual MeetingSD-101 demonstrates consistent and meaningful...
Dynavax Technologies to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26
February 12, 2019 16:05 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines...
Heather Rowe Named Dynavax’s Vice President of Investor Relations and Corporate Communications
January 29, 2019 16:05 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines...
Sam’s Club and Dynavax Technologies Corporation Announce Collaboration to Make HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Available to Sam’s Club Patients
January 08, 2019 09:00 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a leader in developing immunotherapies based on toll-like receptor (TLR) biology, and Sam’s Club,...
Dynavax to Present at 37th Annual J.P. Morgan Healthcare Conference
January 03, 2019 16:05 ET
|
Dynavax Technologies Corporation
BERKELEY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines...